Patents by Inventor Kazuto Nishio

Kazuto Nishio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240314901
    Abstract: A light source device includes light sources, a light output unit, optical filters, temperature sensors detecting current temperatures of the sources, light quantity sensors detecting current light quantities of light beams before traveling through the filters, a storage, and a processor. The storage stores first correlation information between the temperatures of the sources and spectral information and second correlation information between the spectral information and light quantity of light at the unit. The processor is configured to calculate a variation in the spectral information based on each current temperature and the first information, calculate a variation in the light quantity of the light at the unit caused by a change in the spectral information based on the variation in the spectral information and the second information, and calculate a light-quantity correction amount for each of the sources based on the variation in the light quantity and the current light quantity.
    Type: Application
    Filed: May 30, 2024
    Publication date: September 19, 2024
    Applicant: OLYMPUS MEDICAL SYSTEMS CORP.
    Inventors: Koji MATSUMOTO, Masahiro NISHIO, Kazuto FUJIWARA
  • Patent number: 11879150
    Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient would be advantageous. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: January 23, 2024
    Assignees: YAKULT HONSHA CO., LTD., KINKI UNIVERSITY
    Inventors: Kazuto Nishio, Yoshihiko Fujita
  • Publication number: 20190002988
    Abstract: The present invention relates to a RET fusion gene such as a CCDC6-RET fusion gene as a biomarker to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments. The present invention also relates to specific uses of said specific compound in the treatment of cancers.
    Type: Application
    Filed: December 5, 2016
    Publication date: January 3, 2019
    Inventors: Hidetoshi HAYASHI, Kazuhiko NAKAGAWA, Kazuto NISHIO, Kunio OKAMOTO, Kazuko SAKAI, Toshio SHIMIZU, Masayuki TAKEDA, Kaoru TANAKA
  • Publication number: 20180285521
    Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient has not been available. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.
    Type: Application
    Filed: September 23, 2016
    Publication date: October 4, 2018
    Applicants: YAKULT HONSHA CO., LTD., KINKI UNIVERSITY
    Inventors: Kazuto NISHIO, Yoshihiko FUJITA
  • Patent number: 8802384
    Abstract: The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: August 12, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tokuzo Arao, Kanae Kudo, Kazuhiko Nakagawa, Kazuto Nishio
  • Publication number: 20130314526
    Abstract: Provided is a cell concentration/purification device having a function of successively locating cells in a specific area of a microchannel, and a function of sequentially capturing cell images by use of light from a plurality of monochromatic light sources on an image basis, and performing comparative analysis of the cell images to recognize individual cells based on information on the shape of the cells and an absorption spectral distribution of the cells or inside of the cells, thereby selectively separating/purifying the cells.
    Type: Application
    Filed: September 16, 2011
    Publication date: November 28, 2013
    Inventors: Kenji Yasuda, Hideyuki Terazono, Hyonchol Kim, Masahito Hayashi, Akihiro Hattori, Kazuto Nishio, Tokuzo Arao, Yohei Miyagi, Takashi Ohtsu
  • Publication number: 20130085081
    Abstract: Disclosed are a method of detecting the presence or absence of a single nucleotide polymorphism of a gene, for prediction of the risk of developing drug-induced lung injury, or for improving a therapeutic method, and a kit for carrying out the detection method. The detection method is characterized by comparing an ABCB1 gene in a biological sample with a wild-type ABCB1 gene to detect the presence or absence of a single nucleotide polymorphism in the ABCB1 gene in the biological sample, in particular, by determining the nucleotide at position 3751 of the CDS of the ABCB1 gene. The kit comprises an oligonucleotide probe which specifically binds to a single nucleotide polymorphism in an ABCB1 gene under selective binding conditions, or an oligonucleotide primer which amplifies a nucleic acid sequence comprising a single nucleotide polymorphism in an ABCB1 gene.
    Type: Application
    Filed: June 8, 2011
    Publication date: April 4, 2013
    Applicants: National Cancer Center, Kinki University, Mitsubishi Chemical Medience Corporation
    Inventors: Fumiaki Koizumi, Shintaro Kanda, Tomohide Tamura, Koichi Goto, Masaru Sekijima, Akira Ohide, Kazuto Nishio
  • Patent number: 8372647
    Abstract: The present invention provides novel markers for diagnosing pancreatic cancer, and methods for determining if a subject has pancreatic cancer utilizing the markers, etc. The methods involve comparing mass-spectrometric peaks of certain sugar chains, obtained from patients' blood and determining if there is a significant decrease in peak intensity, compared with corresponding peaks from patients without pancreatic cancer.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: February 12, 2013
    Assignee: Sumitomo Bakelite Company Limited
    Inventors: Tokuzo Arao, Kazuko Matsumoto, Kazuto Nishio, Hiroki Sakamoto, Masayuki Kitano, Masatoshi Kudo
  • Patent number: 8207357
    Abstract: An antitumor agent which is not easily excreted from tumor cells and is suitable for a topical treatment. Specifically disclosed is a rotaxane compound with contains a compound represented by chemical formula 1 as the base structure. (In chemical formula 1, m?2, n?3, and X represents an anionic molecule or an anionic atom.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: June 26, 2012
    Assignees: Wan Station Co., Ltd., Tokyo Institute of Technology, Fukuoka University, Kinki University
    Inventors: Toshikazu Takata, Yasuhito Koyama, Kazuko Nakazono, Toshihide Hasegawa, Young-Gi Lee, Nobufumi Ono, Kazuto Nishio, Yoshihiko Fujita
  • Publication number: 20110237807
    Abstract: An antitumor agent which is not easily excreted from tumor cells and is suitable for a topical treatment. Specifically disclosed is a rotaxane compound with contains a compound represented by chemical formula 1 as the base structure.
    Type: Application
    Filed: October 21, 2009
    Publication date: September 29, 2011
    Applicants: WAN STATION CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY, FUKUOKA UNIVERSITY, KINKI UNIVERSITY
    Inventors: Toshikazu Takata, Yasuhito Koyama, Kazuko Nakazono, Toshihide Hasegawa, Young-Gi Lee, Nobufumi Ono, Kazuto Nishio, Yoshihiko Fujita
  • Publication number: 20110065141
    Abstract: The present invention is to provide a novel marker for diagnosing pancreatic cancer, a method for determining if a subject has pancreatic cancer utilizing the marker, etc. The present inventors collected blood from patients of 78 cases in total including patients of 24 cases with pancreaticobiliary-duct benign disorder (16 gallstone cases and 8 pancreatitis cases) and patients of 54 cases with pancreatic cancer, and mass spectrometry was performed on N-linked sugar chains in plasma. From the 74 mass-spectrometric peaks detected, 65 sugar chains were extracted based on the results of PAM analysis. These extracted sugar chains were then used to predict pancreatic cancer or pancreaticobiliary-duct benign disorder, to correctly diagnose 74% cases.
    Type: Application
    Filed: May 8, 2009
    Publication date: March 17, 2011
    Applicant: SUMITOMO BAKELITE COMPANY LIMITED
    Inventors: Tokuzo Arao, Kazuko Matsumoto, Kazuto Nishio, Hiroki Sakamoto, Masayuki Kitano, Masatoshi Kudo
  • Publication number: 20100233705
    Abstract: The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy.
    Type: Application
    Filed: March 9, 2010
    Publication date: September 16, 2010
    Inventors: Tokuzo ARAO, Kanae KUDO, Kazuhiko NAKAGAWA, Kazuto NISHIO
  • Publication number: 20080286785
    Abstract: The invention provides a method of detecting ErbB receptor mutations comprising the steps of providing a bio-fluid sample from a patient; extracting DNA from said sample; and screening said DNA for the presence of one or more mutations that alter tyrosine kinase activity in the receptor.
    Type: Application
    Filed: April 7, 2008
    Publication date: November 20, 2008
    Applicant: AstraZeneca UK Limited
    Inventors: Kazuto Nishio, Hideharu Kimura, Kazuo Kasahara
  • Patent number: 6683083
    Abstract: Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formula [1]: wherein R represents: or a pharmaceutically acceptable salt thereof. Compared with conventional anticancer agents, these agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesions.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 27, 2004
    Inventors: Noboru Kaneko, Kazuto Nishio